<DOC>
	<DOCNO>NCT00501605</DOCNO>
	<brief_summary>Single centre recruit approximately 80 patient give rise single , follow multiple , ascend oral dose AZD2171 , assess safety tolerability AZD2171 patient solid tumor metastatic liver disease .</brief_summary>
	<brief_title>Phase I Study With AZD2171 Patients With Advanced Solid Malignant Tumors Liver Metastases</brief_title>
	<detailed_description />
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Cediranib</mesh_term>
	<criteria>Provision write informed consent Male/female , 18 yr WHO status 02 Refractory advance solid tumor Radiotherapy within 4 week start AZD2171 treatment Low haemoglobin level Low platelet neutrophil count</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2009</verification_date>
	<keyword>Phase I</keyword>
	<keyword>AZD2171</keyword>
	<keyword>advanced solid tumor</keyword>
</DOC>